• RXi and Karolinska Institutet target solid tumour therapy pharmaceutical-technology
    August 17, 2018
    US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and improve immuno-oncology treatments for solid tumours.
  • RXi Receives Patent from USPTO americanpharmaceuticalreview
    May 18, 2018
    RXi Pharmaceuticals has been granted a patent from the United States Patent and Trademark Office (USPTO) for the methods of use of sd-rxRNAs targeting Connective Tissue Growth Factor (CTGF) for the treatment or prevention of fibrotic disorders,
PharmaSources Customer Service